Bespoke Wheel Manufacturer ANRKY Engages Digital Silk to Drive 40% Higher Online Growth

MIAMI, Sept. 8, 2026 /PRNewswire/ -- A wheel can change the character of an entire vehicle. For ANRKY Wheels, the process goes far beyond choosing a design. Every wheel is engineered around the vehicle, from its construction and dimensions to its finish and fitment, then precision-machined and finished in the United States.

Digital Silk has brought that same bespoke philosophy to ANRKY's digital experience with a new website that turns the brand's engineering, craftsmanship and custom builds into an immersive online showroom. Launched May 27, 2026, the new site gives customers a new way to explore ANRKY's forged wheels, discover thousands of vehicle builds and move from inspiration to configuration and quote.

The new experience is already showing measurable results. Since launch, ANRKY's organic search traffic has increased by approximately 40%, while keywords ranking in Google's top three positions have grown more than 15 times, according to Ahrefs data.

See ANRKY's new website at https://anrky.com/

Built Around the Art of the Custom Build

ANRKY's wheels are designed for customers who want more than an off-the-shelf product. The new website reflects that mindset, with options to explore wheel constructions, finishes, sizes and fitments alongside examples of how different designs work with luxury and performance vehicles.

Digital Silk restructured the experience around configuration and discovery, with clear paths through the wheel collection and an easier route from a specific vehicle or finish to a potential build. Persistent "Request a Quote" and "Register a Product" calls to action connect product research with the next step.

"ANRKY has built its reputation by treating every wheel as an engineered piece of automotive design, not a commodity," said Branko Stojanovic, VP of Digital Silk. "We wanted the digital experience to carry that same combination of precision, individuality and visual impact."

The website also puts ANRKY's engineering process at the center of the brand experience. Manufacturing footage introduces the homepage, while dedicated content explains the process behind ANRKY's forged wheels, from premium aluminum forgings through machining and finishing.

40% More Organic Traffic and 15x More Top Rankings

The website's impact extends beyond the visual experience. Alongside the 40% increase in organic search traffic, ANRKY has seen the number of keywords in Google's top three positions increase by more than 15x, according to Ahrefs.

The site has also seen approximately 20% growth in domain authority, three times as many referring domains, and roughly 3.5 times as many pages with organic visibility compared with the pre-launch baseline.

These gains give ANRKY a stronger digital foundation for customers who search for bespoke wheels, while the new site structure creates more room for future product, vehicle and resource content.

For more information, read our case study on ANRKY Wheels.

About Digital Silk 

Digital Silk is an award-winning Miami Web Design Agency focused on growing brands online. With a team of seasoned experts, Digital Silk creates digital experiences through strategic branding, custom web design, and digital marketing services to help improve visibility and support engagement.

Media Contact 

Jericka Orellano 

PR Specialist 

[email protected]

SOURCE Digital Silk

Share this article

CHEYENNE, Wyo., Sept. 8, 2026 /PRNewswire/ -- U.S. Gold Corp. ("U.S. Gold," the "Company," "we," "our" or "us") (Nasdaq: USAU), a U.S. focused gold and copper exploration and development company, today announces its participation in four key investor conferences during September 2026. Management will attend these events to engage with investors, analysts, and industry peers, highlighting the Company's advanced CK Gold Project in Wyoming and its broader portfolio of exploration assets.

Conference Schedule:

- Moody Capital Solutions - Disruptive Growth & Life Sciences Conference

September 9–10, 2026 The Westin New York Grand Central, New York, NY

Click here to register

- H.C. Wainwright 28th Annual Global Investment Conference September 14–16, 2026 Lotte New York Palace Hotel, New York, NY Investor Registration: Click here to register

- 2026 Precious Metals Summit Beaver Creek September 22–25, 2026 Beaver Creek Resort, Beaver Creek, CO Investor Registration (qualification required): Online Investor Qualification Request Form

- Mining Forum Americas 2026 September 27–30, 2026 The Broadmoor Hotel & Resort, Colorado Springs, CO Registration: Register Here (New attendees: Qualify first here)

U.S. Gold Corp. looks forward to connecting with attendees and sharing updates on its fully permitted CK Gold Project, which features robust economics from the recent Feasibility Study, along with exploration potential at its Keystone project in Nevada and Challis Gold project in Idaho.

About U.S. Gold Corp.

U.S. Gold Corp. is a publicly traded, U.S.-focused gold and copper exploration and development company. The Company has a portfolio of exploration properties. The flagship CK Gold Project is located in southeast Wyoming. The Keystone exploration property is on the Cortez Trend in Nevada. The Challis Gold Project is located in Idaho. For more information, visit www.usgoldcorp.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "plans," "expects" or "does not expect," "is expected," "budget," "scheduled," "intends," "anticipates" or "does not anticipate," "proposed," "aims," "forecast," "estimates," "believes," "continues" and "intend," among others, or variations of such words and phrases or statements that certain actions events or results "may," "could," "would," "might," or "will be taken," "occur" or "be achieved", although not all forward-looking statements include these words or phrases. In addition, any statements that refer to expectations, intentions, projections, guidance, potential or other characterizations of future events or circumstances contain forward-looking statements. These forward-looking statements may include statements related to the Company's CK Gold Project, including its anticipated benefits, the exploration potential at the Keystone and Challis Gold projects, the Company's business position, and the investor conference discussed in this release and the Company's participation therein and topics to be discussed. Forward-looking statements are not historical facts nor assurances of future performance but instead represent management's expectations, estimates and projections regarding future events or circumstances. Forward-looking statements are based on our opinions, estimates and assumptions that we considered appropriate and reasonable as of the date such information is stated, subject to known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks described in the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov. The Company undertakes no duty to correct or update any forward-looking statements, except in accordance with applicable securities laws.

For additional information, please contact:

U.S. Gold Corp.

Investor Relations

Phone: +1 800-557-4550

Email: [email protected]

SOURCE U.S. Gold Corp.

Share this article

Accomplished marketing leader brings more than two decades of brand-building and customer

engagement expertise to The Vitamin Shoppe's next chapter of innovation and growth

SECAUCUS, N.J., Sept. 8, 2026 /PRNewswire/ -- The Vitamin Shoppe®, a leading specialty retailer of health and wellness products, today announced the appointment of Kimberley Gardiner as Executive Vice President, Chief Marketing and Growth Officer, effective immediately. Gardiner will report directly to Chief Executive Officer Sharon Leite and join the company's executive leadership team.

Gardiner joins The Vitamin Shoppe from Tractor Supply Company, where she served as Senior Vice President and Chief Marketing Officer since 2022, leading strategic marketing across national, regional, and local initiatives for one of America's largest retailers with more than 2,400 Tractor Supply stores. She helped advance the company's brand and digital transformation, strengthening its distinctive Life Out Here brand positioning and expanding the use of customer data, performance marketing, and omnichannel engagement. Gardiner also oversaw loyalty marketing for Neighbor's Club, which grew to more than 40 million members during her tenure.

In her new role, Gardiner will lead The Vitamin Shoppe's marketing organization and play a pivotal role in the continued evolution of the brand as a more digitally connected and customer-centric wellness platform. She will oversee brand strategy and creative, performance marketing, e-commerce, CRM and personalization, loyalty, and corporate communications and public relations. Gardiner will focus on using customer insights and data to strengthen brand relevance, accelerate acquisition and loyalty, and create a more personalized experience across stores and digital channels.

Gardiner will also work closely with the merchandising organization and brand partners to elevate product storytelling and bring emerging wellness trends and innovation to life for customers.

"Kimberley is an exceptional marketing leader with a proven ability to reinvent established brands and turn customer insights into measurable growth," said Leite. "As The Vitamin Shoppe prepares to celebrate its 50th anniversary next year, we have an opportunity to build on decades of customer trust and loyalty while reimagining how we engage with the modern wellness consumer. Kimberley brings the experience and vision to help us reach new audiences and create more personalized experiences across every touchpoint. I look forward to partnering with her to shape The Vitamin Shoppe's next chapter."

Prior to Tractor Supply, Gardiner served as Chief Marketing Officer at Volkswagen of America, where she led brand strategy, retail content, media planning, dealer marketing operations, and consumer experience marketing. She previously held senior marketing leadership positions at Mitsubishi Motors North America and Kia Motors America and served as Chief Marketing Officer and Vice President of Operations for digital asset management company 5th Kind. Earlier in her career, Gardiner spent 15 years at Toyota Motor Sales, USA in roles of increasing responsibility.

"The Vitamin Shoppe has spent nearly five decades helping millions of people navigate the changing world of health and wellness, a mission that reflects my deep interest in how people can live and feel better," said Gardiner. "I'm excited to build on that legacy and bring fresh thinking to how we tell our story and connect with consumers across retail and digital. I look forward to working with Sharon and the team to create a more dynamic and relevant brand experience designed for the ways consumers discover, shop, and engage with wellness today."

Gardiner earned a Bachelor of Arts in Communication from Mills College and an MBA from Indiana University's Kelley School of Business. She serves on the National Retail Federation Marketing Executives Council and the PopTech Advisory Board.

About The Vitamin Shoppe®

The Vitamin Shoppe® is an omnichannel specialty retailer and wellness lifestyle company with the mission to provide customers with the most trusted products, guidance, and services that support health and performance in every stage of life. Founded in 1977 and headquartered in Secaucus, New Jersey, The Vitamin Shoppe today is an innovation-focused destination for first-to-market brands and breakthrough products, offering a comprehensive assortment of vitamins, supplements, sports nutrition, and on-the-go functional foods and beverages. Beyond hundreds of national brands, its offering includes the proprietary brands The Vitamin Shoppe®, Vthrive The Vitamin Shoppe®, BodyTech®, BodyTech® Elite, plnt®, ProBioCare®, and True Athlete®. The Company serves customers through more than 640 stores nationwide, providing personalized support from knowledgeable Health Enthusiast associates, and online at www.vitaminshoppe.com. It operates strategic partnerships in select international markets in Asia, South America, Central America, and the Caribbean. The Vitamin Shoppe proudly supports the health and wellness of communities through longstanding partnerships with Vitamin Angels and Team Red, White & Blue.

SOURCE The Vitamin Shoppe

Share this article

Reduced cost and expanded scholarships increase access to UMHS's signature Accelerated Review Program, building the confidence, skills, and academic foundation future physicians need to thrive

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- The University of Medicine and Health Sciences (UMHS), a small, mission-driven medical school with a commitment to student success and a legacy of successful residency placements in the United States and Canada, today announced a 35% reduction in tuition for its Accelerated Review Program (ARP), effective May 2026. The new ARP tuition rate will be $7,000.

Designed to help students strengthen foundational science knowledge and develop the study strategies needed to succeed in medical school, the one-semester ARP has become a cornerstone of UMHS's student success model and reflects the university's commitment to individualized medical education. The program supports students as they transition into the rigor of medical school while contributing to UMHS's 96% student retention rate and 94% overall residency Match rate.

Many successful UMHS graduates credit ARP with helping them build the discipline, confidence, and academic skills that prepared them to excel not only in medical school, but also during clinical rotations, residency training, and their careers as physicians.

What's New:

- UMHS is reducing tuition for the Accelerated Review Program by 35%, lowering the cost to $7,000 beginning May 2026.

- Students who earn a grade of B or higher in ARP automatically qualify for a $7,000 ARP Success Scholarship applied toward UMHS tuition in the Basic Sciences program.

- ARP students who successfully complete the program automatically progress into Semester 1 of the UMHS MD program.

Why it Matters:

Medical school is academically demanding, and students who enter with strong study habits, confidence, and foundational knowledge are better positioned for long-term success. UMHS developed ARP to help students build those skills before beginning the MD curriculum through targeted academic preparation, individualized support, and early exposure to the pace and expectations of medical school.

The program is especially valuable for non-traditional students, career changers, students returning to academics after time away, and applicants who would benefit from additional preparation before beginning medical school.

Unlike many post-baccalaureate or master's programs that require one to two years of additional coursework without guaranteeing admission to medical school, ARP can be completed in 15 weeks and provides direct progression into the UMHS MD program upon successful completion.

Students work closely with faculty in a highly personalized learning environment while strengthening competency in foundational sciences, medical terminology, study strategies, test-taking skills, professionalism, and wellness. ARP students also gain early exposure to the same systems-based curriculum and faculty they will encounter throughout the Basic Sciences program.

By lowering tuition for ARP, UMHS aims to make the program more accessible while helping students reduce debt before entering medical school.

What it delivers:

- A direct pathway into medical school – Students who successfully complete ARP automatically matriculate into Semester 1 of the UMHS MD program.

- Preparation for long-term success – ARP equips students with the study strategies, discipline, confidence, and academic foundation necessary to thrive throughout medical school and residency.

- Support for non-traditional and academically diverse students – The program helps students strengthen time management, critical thinking, test-taking, and learning skills before beginning medical school coursework.

- An accelerated alternative to post-bacc and master's programs – ARP can be completed in one semester rather than one to two years.

- Personalized instruction and faculty mentorship – Students learn from the same experienced faculty who teach in the Basic Sciences program in a highly supportive, small-class environment.

- Flexible learning options – Students may attend ARP online from home or in person at the UMHS state-of-the-art campus in St. Kitts, with access to anatomy labs, libraries, and academic support resources.

- A head start on life in St. Kitts – ARP students have the opportunity to experience life on the island before beginning the MD program, building friendships, connecting with faculty and staff, and developing a strong support network that helps ease the transition into medical school.

"Medical school is challenging, and students deserve every opportunity to succeed from the moment they begin their journey," said Warren Ross. "The Accelerated Review Program has helped students build the confidence, discipline, and academic foundation needed to thrive in medical school and beyond. By reducing tuition, we are expanding access to a program that has already transformed outcomes for many aspiring physicians."

Students interested in applying to UMHS or learning more about the Accelerated Review Program can begin the application process online are encouraged to visit the UMHS Accelerated Review Program page.

Frequently Asked Questions (FAQ's)

- What is the Accelerated Review Program (ARP)?

The ARP is a one-semester preparatory program designed to help students strengthen their academic foundation and develop the study skills needed to succeed in medical school. Students receive individualized academic support, faculty mentorship, and personalized guidance while completing coursework across foundational Basic Science disciplines.

- Who is the ARP designed for?

The program is ideal for students seeking additional preparation before beginning medical school, including non-traditional students, career changers, students returning to academics after time away, and applicants looking to strengthen their academic readiness before entering a rigorous MD curriculum.

- How does ARP differ from a post-baccalaureate or master's program?

Unlike many post-bacc or master's programs that can take one to two years and do not guarantee admission to medical school, ARP is completed in 15 weeks and provides direct progression into the UMHS MD program for students who complete it successfully.

- What makes UMHS different from other Caribbean medical schools?

UMHS emphasizes personalized medical education through small class sizes, individualized student support, and a 7:1 student-to-faculty ratio. Students receive direct access to faculty, mentors, learning specialists, and academic advisors throughout medical school, along with extensive USMLE preparation and clinical training opportunities across the U.S., Puerto Rico, and Canada.

- What is UMHS' student retention rate?

UMHS has a 96% student retention rate, one of the highest among Caribbean medical schools. The university attributes this success to its supportive learning environment, faculty accessibility, mentorship, and long-term investment in student success.

- What is UMHS' residency Match rate?

UMHS has achieved a 94% overall residency Match rate, with graduates securing residency placements throughout the United States, Puerto Rico, and Canada, including competitive residency programs and premier teaching hospitals.

About UMHS

The University of Medicine and Health Sciences (UMHS) is a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada. UMHS was founded in 2007 by medical education pioneers Warren Ross and Robert Ross to deliver a highly personalized school experience. Graduates of UMHS earn a Doctor of Medicine degree (MD) and qualify to practice medicine throughout the United States and Canada. Students begin their Basic Science studies in St. Kitts and Nevis and complete their clinical training in the United States and Canada. With an unprecedented 96% student retention rate, the vast majority of students who begin their medical studies at UMHS go on to obtain residencies. For more information, visit the UMHS Official Website.

SOURCE University of Medicine and Health Sciences, St. Kitts

Share this article

Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy

SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease. The Company plans to initiate the clinical trial in the near term.

The IND clearance marks the transition of the first-in-class new drug from preclinical research into clinical development.

About AP308

AP308 is a first-in-class engineered recombinant IgA protease aiming for the functional cure of IgAN. The drug is developed based on an IgA protease derived from Thomasclavelia ramosa, a human commensal bacterium, and can cleave IgA1, galactose-deficient IgA1 (Gd-IgA1), polymeric IgA and IgA immune complexes, and directly clears IgA immune complexes and complement C3 already deposited in the glomeruli; in preclinical studies, it acted within minutes without affecting other immunoglobulins such as IgG and IgM.[1]

In January 2022, Alebund worked together with Peking University First Hospital ("PUFH") on developing IgA proteases into potential IgAN treatment and entered into a license agreement with PUFH. The Company has since developed and nominated AP308 as a drug candidate using its proprietary Long-Acting Protease Engineering Platform. The platform displays excellent stability and developability, extends circulating half-life, reduces renal clearance, and lowers immunogenicity while preserving the protease's potent cleavage activity against IgA1, thereby enabling long-acting, low-frequency dosing. The Company holds the global rights to develop, manufacture, and commercialize AP308.

IgA Nephropathy and Unmet Medical Need

IgAN is the most common primary glomerulonephritis worldwide. It is characterized by the deposition of IgA-containing immune complexes in the glomeruli, which leads to inflammation and progressive kidney damage with a poor long-term prognosis. Long-term cohort studies in China and the United Kingdom show that, under current treatment strategies, median kidney survival is approximately 11 to 12 years and most patients progress to end-stage renal disease within 10 to 15 years of diagnosis, with approximately 60% of patients in the Chinese cohort reaching end-stage renal disease within 15 years.[2][3] According to China Insights Consultancy, there were approximately 9.5 million IgAN patients globally in 2025, including approximately 5.1 million in China, more than half of the global total and the largest IgAN patient population in the world.[4] While existing and emerging therapies mainly target IgA production or downstream inflammation, strategies to directly clear IgA immune complexes already deposited in the kidney remain to be further explored.[1] By directly cleaving and clearing pathogenic IgA and IgA immune complexes already deposited in the glomeruli, AP308 has the potential to address this unmet medical need.

Preclinical Data

In a humanized mouse model of IgAN, once-weekly subcutaneous dosing of AP308 over an eight-week treatment period reduced circulating human IgA and IgA immune complexes by approximately 80% relative to controls; at the end of treatment, histological examination confirmed that glomerular IgA deposits were almost completely cleared, proteinuria decreased significantly, and kidney pathology improved markedly, while repeated dosing produced no signals of liver or kidney toxicity and no significant increase in anti-drug antibody titers. In a separate paired pre- and post-treatment design, a single dose completely cleared pre-existing chronic glomerular IgA and complement C3 deposits within seven days. These preclinical results were published in May 2026 in Kidney International, the official journal of the International Society of Nephrology.[1]

References

About Alebund Pharmaceuticals

Alebund Pharmaceuticals (09637.HK) is a biopharmaceutical company focused on kidney disease and related chronic conditions, aiming to bring better therapies to patients worldwide. It has one of the broadest renal-focused pipelines and an integrated platform spanning R&D, manufacturing and commercialization. Its portfolio comprises seven investigational drug candidates and one commercialized product, Mircera®. Three of the candidates are at the clinical stage: AP301 (China pivotal Phase III trial completed, NDA accepted for review by the NMPA, global MRCT ongoing), AP306 (Phase II) and AP303 (Phase I), and the IND application for AP308 has also been cleared by the U.S. FDA. Together they address chronic kidney disease (CKD) and its complications, including hyperphosphatemia, renal anemia, IgA nephropathy, diabetic kidney disease, FSGS and ADPKD. Alebund has built a manufacturing site in Yangzhou, Jiangsu to support the future commercial manufacturing of AP301 and other pipeline products and has obtained a Drug Manufacturing License (Category B) issued by the Jiangsu Provincial Drug Administration. The Company has also established a dedicated nephrology sales team responsible for the commercialization of relevant products in China. For more information, visit www.alebund.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding clinical development plans, expected timing of data, product potential and future development. These statements are based on the Company's judgments and assumptions as of the date of this press release and are subject to various risks and uncertainties; actual results may differ materially from such forward-looking statements. This press release does not constitute an offer to sell or a solicitation of an offer to purchase any securities.

SOURCE Alebund Pharmaceuticals

Share this article

VANCOUVER, BC, Sept. 8, 2026 /PRNewswire/ -- Nevada Organic Phosphate Inc. ("NOP" or the "Company") (CSE: NOP) (OTCQB: NOPFF), a B.C. based leader in organic sedimentary phosphate exploration, is pleased to announce that it has retained P&E Mining Consultants Inc. ("P&E") to provide independent technical support for its wholly owned Murdock Mountain Property in Elko County, Nevada.

P&E Mining Consultants Inc. is a well‑established mining consultancy whose associates have extensive experience in geological interpretation, 3D geologic modelling, Mineral Resource and Mineral Reserve Estimates (MRE), Preliminary Economic Assessments (PEA), Feasibility Studies (FS), property evaluations, mine design, production scheduling, operating and capital cost estimation, and metallurgical engineering.

P&E also brings direct phosphate‑sector experience, including work on:

First Phosphate Corp. - MRE, PEA, FS

Nuinsco Resources Limited - MRE

Fosfatos del Pacífico S.A., Peru - MRE

Fosfatos de Taltal SpA, Chile - MRE & process guidance

Their direct engagement will support NOP's long-term planning including: ongoing technical evaluation, geological modelling, and staged de‑risking of the Murdock Mountain sedimentary phosphate horizon.

Robin Dow, CEO, stated: "Retaining P&E Mining Consultants strengthens our technical foundation as we continue advancing the Murdock Mountain project. Their experience with phosphate, resource modelling and technical reporting aligns well with our disciplined approach to project development and regulatory compliance."

"P&E's involvement with our team will help us refine our geological interpretation and support the next phases of technical work and reporting at Murdock Mountain," said Garry Smith, P.Geo., Director and Qualified Person for Nevada Organic Phosphate. "Their experience in phosphate modelling and project evaluation will contribute to a more robust understanding of the project as we continue systematic exploration and long-term advancement."

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF)

NOP is a junior exploration company with an organic sedimentary raw rock phosphate bed, 6.6 kilometres long, in northeast Nevada. Additional applications extend the potential strike of rock phosphate to over 30 kilometres. This is believed to be the only known large-scale organic sedimentary phosphate project in North America. It is situated close to the main highway to Montello/Elko, Nevada, and near the rail head to California or the East Coast.

Neither the Canadian Securities Exchange nor its regulations services providers have reviewed or accept responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements and information ("FLSI") within the meaning of applicable securities laws. FLSI may include expectations, anticipations, beliefs, opinions, plans, intentions, estimates, forecasts, projections, guidance or other similar statements and information that are not historical facts. All statements which are not historical statements are considered FLSI. All FLSI is based on assumptions, which may prove inaccurate, and subject to certain risks and uncertainties, including without limitation those risks and uncertainties identified in the Company's public securities filings, which may cause actual events or results to differ materially from those indicated or implied in FLSI. Accordingly, readers should not place undue reliance or value on FLSI. Although the Company believes that the expectations reflected in any FLSI in this news release are reasonable at the present time, it can give no assurance that such FLSI will prove to be correct. Any FLSI in this news release is made as of the date hereof and the Company undertakes no obligations to publicly update or revise any FLSI, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. Any FLSI in this news release is expressly qualified in its entirety by this cautionary statement.

SOURCE Nevada Organic Phosphate Inc.

Share this article

Festival of Lights in Concert 2026 erneut mit weltbekannten DJs - Magische Symbiose aus Licht- und Klangkunst im weltberühmten Berliner Dom

Berlin (ots)

Das international gefeierte Festival of Lights Berlin setzt die Erfolgsgeschichte seiner Konzerte im Berliner Dom auch in diesem Jahr fort: Vom 13. bis 17. Oktober 2026 wird der monumentale Innenraum der weltberühmten Kirche am Lustgarten bereits zum dritten Mal zum Schauplatz für ein spektakuläres Zusammenspiel aus 3D-Videokunst und elektronischer Musik. An fünf Abenden mit insgesamt zehn Konzerten erwarten die Besucherinnen und Besucher einzigartige Show-Erlebnisse aus Licht, Ambient-Sound und tiefen Emotionen.

Für das diesjährige Line-Up konnten erneut weltbekannte Musiker und DJs gewonnen werden: Alle Farben, Westbam, Klangkarussell, Anja Schneider, Chris Bekker sowie Ukai Ndame verwandeln den Dom abseits gewohnter Club-Sets in ein außergewöhnliches Gesamtkunstwerk. Dazu gehört eigens auf die Musik-Sets abgestimmte dreidimensionale Videokunst, die das Innere das Doms buchstäblich in einem völlig anderen Licht erscheinen lässt. Jedes der zehn Konzerte ist einzigartig: so unterschiedlich wie die Musik ist auch die jeweilige Videokunst. Keine Show gleicht der anderen.

Birgit Zander, Gründerin & Kuratorin des Festival of Lights:

"Stellen Sie sich vor: Sie betreten den ehrwürdigen Berliner Dom. Der Raum ist dunkel. Ein leiser Klang beginnt zu vibrieren. Plötzlich erweckt die weltbekannte dreidimensionale Lichtkunst des Festival of Lights das Innere des Doms zum Leben - es pulsiert, tanzt und durchdringt die monumentale Architektur bis ins kleinste Detail. Bunte, leuchtende Farben und aufwändige Projektionen füllen den Raum, gleiten über Gewölbe und Wände. Musik und Licht verschmelzen - und treffen mitten ins Herz der Besucherinnen und Besucher. 'Festival of Lights in Concert' ist weit mehr als eine Konzertreihe - es ist eine intensive Reise durch Klang- und Lichtkunst, die den gesamten Raum und die Menschen darin einhüllt und nicht mehr loslässt."

Das Line-up 2026

- Alle Farben:

Mit über 20 Jahren Erfolgsgeschichte und als einer der bekanntesten deutschen Dance-Musik-Exporte hebt Alle Farben seine Live-Performances im Dom auf ein ganz neues Level.

- Anja Schneider:

Die Berliner Wegbereiterin der House- und Technokultur prägt die Szene seit den 1990er-Jahren. Ihr Sound zeichnet sich durch große emotionale Tiefe, elegante Melodik und energetische Nuancen aus.

- Chris Bekker:

DJ, Producer und Resident-DJ im Berliner KitKat Club. Seit 2016 produziert er exklusive Sounds für die Wahrzeichen des Festival of Lights und präsentiert im Dom neue und hochemotionale elektronische Klangwelten.

- Klangkarussell:

Das Duo steht für elektronische Musik mit cineastischer Tiefe, organischer Wärme und atmosphärischen Momenten voller Licht und Euphorie.

- Westbam:

DER Pionier der deutschen Rave- und Technokultur, Mitbegründer des Berlin Techno Sounds, Initiator legendärer Events wie "Mayday", DJ der ersten Stunde der Berliner "Love Parade" sowie Wegbereiter der Techno-Bewegung.

- Ukai Ndame:

Sie verbindet House Music mit Emotion, Eleganz und kultureller Vielfalt, um unvergessliche Momente im Raum zu schaffen.

Keyfacts & Termine

- Ort: Innenraum Berliner Dom

- Termine: 13. bis 17. Oktober 2026

- Umfang: 10 Konzerte an 5 Abenden (Vorstellungen zwischen 19:30 und 22:00 Uhr)

- Genres: Elektronisch, Ambient, Housig, Neoklassisch, Technoid

- Tickets & Infos: Limitierte Sitzplätze pro Show, Vorverkauf unter www.festival-of-lights.de/de/inconcert-2026

- Alle Konzerte des letzten Jahres waren restlos ausverkauft.

- Auch 2026 ist die Nachfrage hoch: Für die Show am 14.10.2026 sind bereits keine Tickets mehr erhältlich.

Über das Festival of Lights:

Das Festival of Lights zählt zu den bekanntesten Lichtkunstfestivals weltweit.

Jedes Jahr im Oktober verwandelt es Berlin für zehn Nächte in eine riesige Open-Air-Galerie. Die Stadt wird zur Bühne, ikonische Wahrzeichen, Monumente und Plätze werden mit eindrucksvollen Projektionen und Installationen in Szene gesetzt.

Pressekontakt:

Zander & Partner Event-Marketing GmbH

Savignyplatz 6, 10623 Berlin

E-Mail: presse@festival-of-lights.de

www.festival-of-lights.de

www.facebook.com/FestivalOfLights

www.youtube.com/LightsOnBerlin

www.instagram.com/berlinfestivaloflights

www.instagram.com/folinconcert

Original-Content von: Festival of Lights, übermittelt durch news aktuell

Amtliches Endergebnis: Der klare Sieger der Wahl in Sachsen-Anhalt heißt NIUS

Mehr als 1,3 Millionen Zuschauer: NIUS feiert mit Sondersendung Rekordzahlen und lässt den Wettbewerb weit hinter sich

BERLIN / MAGDEBURG (ots)

Die Landtagswahl in Sachsen-Anhalt verdeutlicht nicht nur eine politische Zäsur in Deutschland, sondern auch den immer schneller fortschreitenden Wandel in der Medienwelt. Mit einer mehrstündigen Sondersendung erreichte NIUS über 1,3 Millionen Zuschauer und erzielte damit einmal mehr Top-Einschaltquoten in der digitalen Berichterstattung. Allein auf YouTube verfolgten in der Spitze mehr als 135.000 Live-Zuschauer zeitgleich die exklusiven Analysen und Reaktionen bei NIUS, der YouTube-Kanal insgesamt erreichte im Juli mehr als 5,2 Millionen Zuschauer.

Das überwältigende Publikumsinteresse am Wahlabend zeigt nun erneut: NIUS hat sich als digitaler Vorreiter in der politischen Live-Berichterstattung an der Spitze etabliert. Wo traditionelle Formate immer mehr an Strahlkraft verlieren, setzt NIUS auf direkte und dynamische Berichterstattung am Puls des Geschehens.

In den vergangenen sieben Tagen war NIUS Live offiziell der größte deutsche Livestream mit durchschnittlich 32.357 Live-Zuschauern in jeder Folge. Damit ist NIUS live jeden Morgen ab 6 Uhr Deutschlands geliebteste Morgenshow.

Zum Umbruch in der politischen Berichterstattung betont NIUS-Chefredakteur Julian Reichelt:

"Der Medienwandel ist kein theoretischer Diskurs mehr, sondern eine tägliche Abstimmung. Die Menschen warten heute nicht mehr brav auf die 20-Uhr-Nachrichten - sie holen sich ihre Informationen dort, wo sie live und ungefiltert stattfinden. Danke an alle, die NIUS als ihre neue Lovebrand gewählt haben. Wir nehmen die Wahl an."

Über NIUS:

NIUS ist Deutschlands schnellstwachsendes Medien-Startup und für immer mehr Menschen die Informationsquelle Nummer 1.

Pressekontakt:

Philippe Fischer

NIUS Presse & Öffentlichkeitsarbeit

Telefon: +49 (0)30 - 2000443-00

E-Mail: kontakt@nius.de

Original-Content von: VIUS SE & Co KGaA, übermittelt durch news aktuell

Aktion von CSL Seqirus ruft zur Grippeimpfung vor dem Oktoberfest auf

München (ots)

Die zweite Ausgabe der Aktion "O'zapft is - aber bitte Grippe-geimpft!" von CSL Seqirus und der Marien Apotheke München hat heute mit einem Pressetermin begonnen. Heute und morgen sind alle Münchner:innen dazu aufgerufen, sich pünktlich vor dem größten Volksfest der Welt gegen die Grippe impfen zu lassen.

Gemeinsam mit Experten aus Medizin und Politik setzen CSL Seqirus und die Marien Apotheke vor der Wiesn und zum Beginn der Grippesaison erneut ein Zeichen für Grippeprävention. Sie nutzen den Anlass, um auf die niedrigschwelligen Impfangebote in Arztpraxen und Apotheken aufmerksam zu machen. Nach dem großen Erfolg im letzten Jahr, als sich über 300 Personen an zwei Tagen impfen ließen, wurde die Aktion in diesem Jahr ausgeweitet. Mehr als 40 Arztpraxen und Apotheken in der Region München beteiligen sich an der Aktion und dem Aufruf, sich vor dem Oktoberfest gegen Grippe impfen zu lassen.

Am heutigen Pressetermin haben folgende Persönlichkeiten teilgenommen, um ihre Unterstützung zum Ausdruck zu bringen:

- Thomas Benkert, Ehrenpräsident der Bundesapothekerkammer (BAK)

- Alexander Almerood, Country Manager, CSL Seqirus Germany

- Prof. Klaus Holetschek, Vorsitzender der CSU-Fraktion im Bayerischen Landtag, Staatsminister für Gesundheit, Pflege und Prävention a.D.

- Prof. Dr. Christoph Spinner, MBA, Ltd. Oberarzt Infektiologie, Klinikum der Technischen Universität München (TUM Klinikum)

Thomas Benkert, Ehrenpräsident der Bundesapothekerkammer (BAK)

"Apotheken leisten bereits heute einen wichtigen Beitrag zur Prävention und ermöglichen vielen Menschen einen unkomplizierten Zugang zur Grippeschutzimpfung. Mit dieser Aktion machen wir sichtbar, wie einfach Vorsorge sein kann. Gerade vor dem Oktoberfest, wenn Millionen Menschen zusammenkommen, möchten wir die Münchnerinnen und Münchner daran erinnern, rechtzeitig an ihren Impfschutz zu denken. Die große Resonanz im vergangenen Jahr hat gezeigt, dass wir mit dieser Aktion viele Menschen erreichen können."

Alexander Almerood, Country Manager, CSL Seqirus Germany

"Als eines der weltweit führenden Unternehmen im Bereich Influenza-Prävention engagiert sich CSL Seqirus für die Entwicklung und Bereitstellung weiterentwickelter* Grippeimpfstoffe sowie die Stärkung der öffentlichen Gesundheit. Auch in dieser Saison, in der die von der WHO empfohlene umfassende Stammanpassung die Impfstoffherstellung vor besondere Herausforderungen gestellt hat, konnten wir unsere Grippeimpfstoffe verlässlich und frühzeitig bereitstellen. Mit unserer Oktoberfest-Initiative bringen wir Wissenschaft, Politik, Apotheken und Arztpraxen zusammen, um möglichst viele Menschen für die Grippeschutzimpfung zu sensibilisieren. Besonders freut uns, dass sich mehr als 40 Apotheken und Arztpraxen in der Region München an der Aktion beteiligen. Denn jede verhinderte Grippeerkrankung schützt nicht nur die Menschen selbst, sondern stärkt auch die Gesundheit unserer Gesellschaft insgesamt."

* Die STIKO bezeichnet im Protokoll ihrer 96. Sitzung vom 17. Juni 2020 sowie in ihren Empfehlungen den MF59-adjuvantierten Impfstoff, Hochdosis-Impfstoff, rekombinanten Impfstoff und zellbasierten Impfstoff als "weiterentwickelte" Impfstoffe.

Prof. Klaus Holetschek, Vorsitzender der CSU-Fraktion im Bayerischen Landtag, Staatsminister für Gesundheit, Pflege und Prävention a.D.

"Mir ist wichtig, dass die Menschen in München gut informiert und gut geschützt in den Herbst gehen. Die Grippe wird schnell unterschätzt. Dabei kann ein rechtzeitiger Impfschutz helfen, sich selbst zu schützen und zugleich Verantwortung für andere zu übernehmen. Gerade vor dem Oktoberfest zeigt Vorsorge auch: Wir passen aufeinander auf."

Prof. Dr. Christoph Spinner, MBA, Ltd. Oberarzt Infektiologie, Klinikum der Technischen Universität München (TUM Klinikum)

"Influenza ist keine harmlose Erkältung, sondern verursacht jedes Jahr erhebliche Krankheitslast, Krankenhausaufenthalte und Arbeitsausfälle. Gerade rund um Großveranstaltungen wie das Oktoberfest gewinnt Prävention an Bedeutung. Die STIKO empfiehlt die jährliche Grippeimpfung insbesondere für Menschen ab 60 Jahre, chronisch Erkrankte und sowie Personen mit erhöhtem Infektionsrisiko durch viele berufliche und private Kontakte. Die gute Nachricht: Mit weiterentwickelten Influenza-Impfstoffen, wie beispielsweise denen von CSL Seqirus, steht eine wirksame und sichere Schutzmaßnahme zur Verfügung. Wer sich jetzt impfen lässt, ist rechtzeitig zum Start der Grippesaison geschützt."

Pressekontakt:

Steffen Becker

APCO

+49 173 490 53 82

sbecker@apcoworldwide.com

Original-Content von: CSL Seqirus, übermittelt durch news aktuell

Vereinigte Lohnsteuerhilfe e.V. - VLH

Privatauto statt Firmenwagen für Dienstreise: Kein Werbungskostenabzug

Neustadt a. d. W. (ots)

Fahrtkosten für Dienstreisen mit dem privaten Auto können grundsätzlich als Werbungskosten steuerlich geltend gemacht werden. Aber Achtung: Steht für Dienstreisen eigentlich ein Firmenwagen zur Verfügung und man entscheidet sich dennoch für das Privatfahrzeug, kann das Finanzamt den Abzug der entsprechenden Werbungskosten verweigern. Das geht aus einem Urteil des Bundesfinanzhofs (BFH) hervor. Der Lohnsteuerhilfeverein Vereinigte Lohnsteuerhilfe e. V. (VLH) erläutert die Details und klärt auf.

Ohne Firmenwagen können Werbungskosten geltend gemacht werden

Wer mit seinem privaten Fahrzeug eine Dienstreise absolviert und die Fahrtkosten nicht vom Arbeitgeber oder der Arbeitgeberin erstattet bekommt, kann diese in der Steuererklärung als Werbungskosten geltend machen. Anders sieht es aus, wenn ein Arbeitnehmer oder eine Arbeitnehmerin über einen Firmenwagen verfügt, statt diesem ein Privatfahrzeug für eine Dienstfahrt nutzt und die Fahrtkosten von der Steuer absetzen möchte. Genau darum ging es in einen Streitfall, der in letzter Instanz beim Bundesfinanzhof (BFH) landete.

Ein Arbeitnehmer verfügte über einen Firmenwagen, den er und seine Ehefrau auch privat nutzen durften. Für drei Dienstreisen nahm er dennoch seinen privaten Pkw und wollte dafür in seiner Steuererklärung Fahrtkosten von rund 3.800 Euro als Werbungskosten geltend machen. Das Finanzamt lehnte dies ab, der Mann klagte - und das Niedersächsische Finanzgericht gab seiner Klage statt. Dagegen wiederum wehrte sich das zuständige Finanzamt, und so landete der Fall als Revision beim BFH.

Privat-Pkw statt Firmenwagen für Dienstreise: Gründe sind entscheidend

Der BFH stellte klar: Werden berufliche Fahrten mit dem Privatwagen durchgeführt, obwohl ein Firmenwagen kostenlos zur Verfügung steht, kommt es auf die Gründe für diese Entscheidung an. Liegt die Nutzung des Privatwagens überwiegend in privaten Motiven begründet und werden diese nach einer sogenannten Angemessenheitsprüfung als unangemessen eingestuft, können die dadurch entstandenen Kosten steuerlich nicht berücksichtigt werden.

Im konkreten Fall nutzte die Ehefrau während der Dienstreisen des Mannes den Firmenwagen. Darin sah der BFH ausschließlich private Motive und die entstandenen Kosten als unangemessen an. Zumal dem Arbeitnehmer bei Nutzung des Firmenwagens keinerlei Fahrtkosten entstanden wären. Deshalb lehnte der BFH den Abzug der Werbungskosten ab, und die Entscheidung des Finanzgerichts wurde aufgehoben (BFH-Urteil VI R 30/24).

Die VLH: Größter Lohnsteuerhilfeverein Deutschlands

Der Lohnsteuerhilfeverein Vereinigte Lohnsteuerhilfe e. V. (VLH) ist mit rund 1,3 Millionen Mitgliedern und bundesweit rund 3.000 Beratungsstellen Deutschlands größter Lohnsteuerhilfeverein. Gegründet im Jahr 1972, stellt die VLH außerdem die meisten nach DIN 77700 zertifizierten Beraterinnen und Berater. Die VLH erstellt für ihre Mitglieder die Einkommensteuererklärung, beantragt sämtliche Steuerermäßigungen, prüft den Steuerbescheid und vieles mehr im Rahmen der Beratungsbefugnis nach § 4 StBerG.

Pressekontakt:

Steffen Gall

Lohnsteuerhilfeverein

Vereinigte Lohnsteuerhilfe e. V. (VLH)

Fritz-Voigt-Str. 13

67433 Neustadt a.d. Weinstraße

Tel.: 06321 4901-0

Fax: 06321 4901-49

E-Mail: presse@vlh.de

Web: www.vlh.de/presse

Original-Content von: Vereinigte Lohnsteuerhilfe e.V. - VLH, übermittelt durch news aktuell